戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  and are important to define in treatment of premenstrual syndrome.
2  and was well tolerated by women with severe premenstrual syndrome.
3  or placebo on symptoms in 20 women with the premenstrual syndrome.
4 contributed only modestly to the etiology of premenstrual syndrome.
5  effects of B vitamins in the development of premenstrual syndrome.
6 tory response is unknown in the treatment of premenstrual syndrome.
7 onin reuptake inhibitor in women with severe premenstrual syndrome and determined the effects of post
8 ogenous 3alpha,5alpha-THP withdrawal such as premenstrual syndrome and postpartum or postmenopausal d
9 reuptake inhibitors are effective for severe premenstrual syndrome and premenstrual dysphoric disorde
10  of premenstrual disorders (PMDs), including premenstrual syndrome and premenstrual dysphoric disorde
11  menopausal women, alleviate the symptoms of premenstrual syndrome, and reduce persistent urinary tra
12 ate 40 species were used for the symptoms of premenstrual syndrome, heavy menstrual bleeding, and dys
13 fter adjusting for smoking, body mass index, premenstrual syndrome, hot flashes, poor sleep, health s
14                   The symptoms of women with premenstrual syndrome improve in response to suppression
15 ausal treatment to vasomotor symptoms, or to premenstrual syndrome in premenopausal women, neglects a
16                                Women without premenstrual syndrome (normal women) participated in a s
17                       Clinically significant premenstrual syndrome (PMS) affects 15-20% of premenopau
18                           Moderate to severe premenstrual syndrome (PMS) affects as many as 20% of pr
19     Premenstrual disorders (PMDs), including premenstrual syndrome (PMS) and premenstrual dysphoric d
20 (4) and delta subunits, using a rat model of premenstrual syndrome (PMS) in which 1-3 mM alcohol pref
21 her minerals might impact the development of premenstrual syndrome (PMS) through multiple mechanisms,
22 onses to placebo medication of patients with premenstrual syndrome (PMS) who were randomly assigned i
23 rlying hypertension might also contribute to premenstrual syndrome (PMS), but whether women with PMS
24                                  Symptoms of premenstrual syndrome (PMS), such as anxiety and seizure
25  being used as first-line therapy for severe premenstrual syndrome (PMS).
26 cle to cycle symptom stability in women with premenstrual syndrome (PMS).
27 tentially involved in the pathophysiology of premenstrual syndrome (PMS).
28  About 5-8% of women thus suffer from severe premenstrual syndrome (PMS); most of these women also me
29 ion, including history of depression, severe premenstrual syndrome, poor sleep, age, race, and employ
30 roids have been implicated in the genesis of premenstrual syndrome, postpartum depression, and other
31 depressant to determine whether efficacy for premenstrual syndrome/premenstrual dysphoric disorder is
32                                In women with premenstrual syndrome, the occurrence of symptoms repres
33 er from continuous dosing with sertraline in premenstrual syndrome treatment.
34                            The 10 women with premenstrual syndrome who were given leuprolide had a si
35                            The 10 women with premenstrual syndrome who were given leuprolide plus est
36 received the same regimen or in 5 women with premenstrual syndrome who were given placebo hormone dur